P=N/A, N=90, Recruiting, Fudan University

P3, N=2570, Not yet recruiting, Montreal Heart Institute

P=N/A, N=130, Completed, Thomas Jefferson University | Active, not recruiting --> Completed

In the xenograft model, the combination treatment suppressed tumor growth by approximately 70%, an effect comparable to paclitaxel (PTX). In contrast to PTX, the combination of rhAPE1/Ref-1 and ASA did not cause hematological toxicity, such as anemia or thrombocytopenia. The combination of rhAPE1/Ref-1 and ASA represents a promising new therapeutic strategy for TNBC by enhancing apoptosis and significantly inhibiting tumor progression in a mouse xenograft model.

P2, N=159, Completed, Stanford University | Active, not recruiting --> Completed

P4, N=18883, Completed, Dartmouth-Hitchcock Medical Center | Active, not recruiting --> Completed

P3, N=5676, Not yet recruiting, Christian Medical College and Hospital, Ludhiana, India

Co-treatment with indomethacin showed no additive toxicity. These findings support IONPs@HES as a biocompatible nanoplatform suitable for vascular-targeted cancer therapy, meriting further in vivo validation.

Notable medications include RANKL inhibitors, which boost immune cell responses; TGF-β inhibitors, which improve T cell infiltration; and metformin, which activates cytotoxic T lymphocytes...On the other hand, aspirin may enhance immune checkpoint inhibitors by blocking the immunological milieu that tumors produce...Future developments in personalized medicine and artificial intelligence may increase the efficacy of drug repurposing in cancer treatment. To fully realize the potential of repurposed medications in enhancing the results for cancer patients, interdisciplinary cooperation between the academic community, business leaders, and regulatory bodies will be required.

P=N/A, N=216, Recruiting, Beijing Tiantan Hospital | Not yet recruiting --> Recruiting

In conclusion, CPX exerts its antitumour effects on HCC through ROS-dependent NLRP3-mediated pyroptosis. This study provides a strong rationale for further clinical exploration and development of CPX-based therapies, offering a promising avenue for improving outcomes in patients with HCC.

P3, N=100, Not yet recruiting, McMaster University